A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients

Inclusion Criteria: * A body weight of 40 to 100 kg for female or 45 to 100 kg for male * A body mass index of 18 to 30 kg/m2 * Subjects who have current history of JC-SAR in previous 2 consecutive years. * Presence (CAP-RAST: ≥2) of IgE specific to Japanese cedar pollens and absence (CAP-RAST: ≤1) of IgE specific to other 4 allergens * Presence of at least 2 symptoms, which are moderate to very severe, in 4 nasal symptoms (runny nose, sneezing, blocked nose, itchy nose) at any time point during allergen exposure in EEC at screening period Exclusion Criteria: * Presence of any symptoms of allergic rhinitis within 1 year except scattering season of cedar pollen or cypress pollen * Subjects who have persistent symptom caused by allergen exposure in EEC at screening period until Day 1 (pre-dose) * Underwent nasal surgery (include laser surgery) to improve nasal symptoms within 2 years * Underwent specific immunotherapy or non-specific immunotherapy within 5 years * Underwent medication of anti-histamine, oral mast cell stabilizer, leukotriene receptor antagonist, prostaglandin D2/thromboxane A2 receptor antagonist, Th2 cytokine inhibitor, corticosteroid (oral form, intra-nasal form, ocular form), or vasoconstrictor within 4 weeks * Underwent medication of corticosteroid (injection form) or anti-IgE antibody within 6 months * Subject who is concerned about exacerbation of the physical condition due to allergen exposure in EEC